Evergreen Therapeutics is a Maryland-based innovative biopharmaceutical company established in 2019 that features "End-to-End" artificial intelligence (AI) as one of its core technologies. In addition to developing our own drug products, we provide consulting services to other pharmaceutical companies worldwide. The company was initiated by 5 former FDA reviewers, including 2 clinical, 1 preclinical, and 2 CMC experts, with about 80+ years of industry experiences combined. Our other core team members come from various multinational pharmaceutical companies.
We have also an office and laboratories in Shenzhen, China. Our regulatory and clinical consulting services cover various therapeutic areas, with the exception of drug products for the treatment of ophthalmic, autoimmune, and obstetric diseases. During the past 3 years, Evergreen has helped 23 Chinese companies submit their IND, ODD, Fast Track, and RMAT to the FDA, and has assisted 7 American and Japanese companies in filing their IND to the NMPA, Chinese regulatory authority. We also serve as a third-party clinical monitor, preclinical auditor, or CMC inspector to help our clients develop their pharmaceutical products outside of their countries.
A company with very strong technical capabilities, Evergreen is committed in using AI technologies to in develop drug products for “unmet medical needs”. At present, Evergreen has 10 drug candidates in its pipeline, 5 of which have already entered into phase I to III clinical stages in the United States. Evergreen has more than 50 patent applications, covering major global pharmaceutical markets including China, the United States, Europe, and Japan.
Evergreen Therapeutics is a Maryland-based innovative biopharmaceutical company established in 2019 that features "End-to-End" artificial intelligence (AI) as one of its core technologies. In addition to developing our own drug products, we provide consulting services to other pharmaceutical companies worldwide. The company was initiated by 5 former FDA reviewers, including 2 clinical, 1 preclinical, and 2 CMC experts, with about 80+ years of industry experiences combined. Our other core team members come from various multinational pharmaceutical companies.
We have also an office and laboratories in Shenzhen, China. Our regulatory and clinical consulting services cover various therapeutic areas, with the exception of drug products for the treatment of ophthalmic, autoimmune, and obstetric diseases. During the past 3 years, Evergreen has helped 23 Chinese companies submit their IND, ODD, Fast Track, and RMAT to the FDA, and has assisted 7 American and Japanese companies in filing their IND to the NMPA, Chinese regulatory authority. We also serve as a third-party clinical monitor, preclinical auditor, or CMC inspector to help our clients develop their pharmaceutical products outside of their countries.
A company with very strong technical capabilities, Evergreen is committed in using AI technologies to in develop drug products for “unmet medical needs”. At present, Evergreen has 10 drug candidates in its pipeline, 5 of which have already entered into phase I to III clinical stages in the United States. Evergreen has more than 50 patent applications, covering major global pharmaceutical markets including China, the United States, Europe, and Japan.
